These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 22460735)

  • 21. High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia.
    Herling M; Patel KA; Weit N; Lilienthal N; Hallek M; Keating MJ; Jones D
    Blood; 2009 Nov; 114(21):4675-86. PubMed ID: 19770358
    [TBL] [Abstract][Full Text] [Related]  

  • 22. miR deregulation in CLL.
    Balatti V; Pekarky Y; Rizzotto L; Croce CM
    Adv Exp Med Biol; 2013; 792():309-25. PubMed ID: 24014303
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Absence of caveolin-1 leads to delayed development of chronic lymphocytic leukemia in Eμ-TCL1 mouse model.
    Shukla A; Cutucache CE; Sutton GL; Pitner MA; Rai K; Rai S; Opavsky R; Swanson PC; Joshi SS
    Exp Hematol; 2016 Jan; 44(1):30-7.e1. PubMed ID: 26435347
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bone marrow stromal cell-derived vascular endothelial growth factor (VEGF) rather than chronic lymphocytic leukemia (CLL) cell-derived VEGF is essential for the apoptotic resistance of cultured CLL cells.
    Gehrke I; Gandhirajan RK; Poll-Wolbeck SJ; Hallek M; Kreuzer KA
    Mol Med; 2011; 17(7-8):619-27. PubMed ID: 21519633
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lessons learned from the Eµ-TCL1 mouse model of CLL.
    Floerchinger A; Seiffert M
    Semin Hematol; 2024 Jun; 61(3):194-200. PubMed ID: 38839457
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Guilty bystanders: nurse-like cells as a model of microenvironmental support for leukemic lymphocytes.
    Filip AA; Ciseł B; Wąsik-Szczepanek E
    Clin Exp Med; 2015 Feb; 15(1):73-83. PubMed ID: 24337970
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells.
    Petlickovski A; Laurenti L; Li X; Marietti S; Chiusolo P; Sica S; Leone G; Efremov DG
    Blood; 2005 Jun; 105(12):4820-7. PubMed ID: 15728130
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Organometallic nucleosides induce non-classical leukemic cell death that is mitochondrial-ROS dependent and facilitated by TCL1-oncogene burden.
    Prinz C; Vasyutina E; Lohmann G; Schrader A; Romanski S; Hirschhäuser C; Mayer P; Frias C; Herling CD; Hallek M; Schmalz HG; Prokop A; Mougiakakos D; Herling M
    Mol Cancer; 2015 Jun; 14():114. PubMed ID: 26041471
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of bone marrow stromal cells on Bcl-2 family members in chronic lymphocytic leukemia.
    Patel V; Chen LS; Wierda WG; Balakrishnan K; Gandhi V
    Leuk Lymphoma; 2014 Apr; 55(4):899-910. PubMed ID: 23837491
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Par-4 overexpression impedes leukemogenesis in the Eµ-TCL1 leukemia model through downregulation of NF-κB signaling.
    Greene JT; Mani R; Ramaswamy R; Frissora F; Yano M; Zapolnik K; Harrington B; Wasmuth R; Tran M; Mo X; McKenna M; Rangnekar VM; Byrd JC; Bondada S; Muthusamy N
    Blood Adv; 2019 Apr; 3(8):1255-1266. PubMed ID: 30987970
    [TBL] [Abstract][Full Text] [Related]  

  • 31. miR-34b/miR-34c: a regulator of TCL1 expression in 11q- chronic lymphocytic leukaemia?
    Cardinaud B; Moreilhon C; Marcet B; Robbe-Sermesant K; LeBrigand K; Mari B; Eclache V; Cymbalista F; Raynaud S; Barbry P
    Leukemia; 2009 Nov; 23(11):2174-7. PubMed ID: 19536169
    [No Abstract]   [Full Text] [Related]  

  • 32. IGHV3-21 gene usage is associated with high TCL1 expression in chronic lymphocytic leukemia.
    Mansouri MR; Sevov M; Aleskog A; Jondal M; Merup M; Sundström C; Osorio L; Rosenquist R
    Eur J Haematol; 2010 Feb; 84(2):109-16. PubMed ID: 19889012
    [TBL] [Abstract][Full Text] [Related]  

  • 33. miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors.
    Sharma S; Pavlasova GM; Seda V; Cerna KA; Vojackova E; Filip D; Ondrisova L; Sandova V; Kostalova L; Zeni PF; Borsky M; Oppelt J; Liskova K; Kren L; Janikova A; Pospisilova S; Fernandes SM; Shehata M; Rassenti LZ; Jaeger U; Doubek M; Davids MS; Brown JR; Mayer J; Kipps TJ; Mraz M
    Blood; 2021 May; 137(18):2481-2494. PubMed ID: 33171493
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of the splenic microenvironment in chronic lymphocytic leukemia development in Eµ-TCL1 transgenic mice.
    Collard JP; McKenna MK; Noothi SK; Alhakeem SS; Rivas JR; Rangnekar VM; Muthusamy N; Bondada S
    Leuk Lymphoma; 2022 Aug; 63(8):1810-1822. PubMed ID: 35258388
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1).
    Decker S; Finter J; Forde AJ; Kissel S; Schwaller J; Mack TS; Kuhn A; Gray N; Follo M; Jumaa H; Burger M; Zirlik K; Pfeifer D; Miduturu CV; Eibel H; Veelken H; Dierks C
    Mol Cancer Ther; 2014 May; 13(5):1231-45. PubMed ID: 24659821
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is miR-29 an oncogene or tumor suppressor in CLL?
    Pekarsky Y; Croce CM
    Oncotarget; 2010 Jul; 1(3):224-7. PubMed ID: 20936047
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The JAK3-selective inhibitor PF-956980 reverses the resistance to cytotoxic agents induced by interleukin-4 treatment of chronic lymphocytic leukemia cells: potential for reversal of cytoprotection by the microenvironment.
    Steele AJ; Prentice AG; Cwynarski K; Hoffbrand AV; Hart SM; Lowdell MW; Samuel ER; Wickremasinghe RG
    Blood; 2010 Nov; 116(22):4569-77. PubMed ID: 20716767
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells.
    Longo PG; Laurenti L; Gobessi S; Sica S; Leone G; Efremov DG
    Blood; 2008 Jan; 111(2):846-55. PubMed ID: 17928528
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of TET and IDH gene expression in chronic lymphocytic leukemia: comparison with normal B cells and prognostic significance.
    Van Damme M; Crompot E; Meuleman N; Maerevoet M; Mineur P; Bron D; Lagneaux L; Stamatopoulos B
    Clin Epigenetics; 2016; 8():132. PubMed ID: 27980696
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD74 is dispensable for development of chronic lymphocytic leukemia in
    Barthel R; Fedorchenko O; Velmans T; Rosen N; Nguyen PH; Reinart N; Florin A; Herling M; Hallek M; Fingerle-Rowson G
    Leuk Lymphoma; 2020 Dec; 61(12):2799-2810. PubMed ID: 32667245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.